NCT05856487View on ClinicalTrials.gov

To Evaluate the Safety and Efficacy of NVP-2203 Tablet in Patients

PHASE3UnknownINTERVENTIONAL
Enrollment

228

Participants

Timeline

Start Date

June 30, 2023

Primary Completion Date

May 31, 2024

Study Completion Date

October 31, 2024

Conditions
Cardiovascular Diseases
Interventions
DRUG

NVP-2203

Take it once daily for 8 weeks orally.

DRUG

NVP-2203-R1

Take it once daily for 8 weeks orally.

DRUG

NVP-2203-R2

Take it once daily for 8 weeks orally.

DRUG

NVP-2203-R3

Take it once daily for 8 weeks orally.

DRUG

NVP-2203 Placebo

Take it once daily for 8 weeks orally.

DRUG

NVP-2203-R1 Placebo

Take it once daily for 8 weeks orally.

DRUG

NVP-2203-R2 Placebo

Take it once daily for 8 weeks orally.

DRUG

NVP-2203-R3 Placebo

Take it once daily for 8 weeks orally.

Trial Locations (1)

16209

RECRUITING

NVPhealthcare, Suwon

Sponsors

Lead Sponsor

NVP Healthcare
All Listed Sponsors
lead

NVP Healthcare

INDUSTRY

NCT05856487 - To Evaluate the Safety and Efficacy of NVP-2203 Tablet in Patients | Biotech Hunter | Biotech Hunter